Consolidated Planning Corp Sells 296 Shares of Eli Lilly and Company $LLY

Consolidated Planning Corp lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 27.1% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 797 shares of the company’s stock after selling 296 shares during the period. Consolidated Planning Corp’s holdings in Eli Lilly and Company were worth $621,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Brighton Jones LLC increased its holdings in Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after acquiring an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC increased its holdings in Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after acquiring an additional 40 shares in the last quarter. Apella Capital LLC increased its holdings in Eli Lilly and Company by 9.4% in the 1st quarter. Apella Capital LLC now owns 1,749 shares of the company’s stock worth $1,318,000 after acquiring an additional 151 shares in the last quarter. Iams Wealth Management LLC increased its holdings in Eli Lilly and Company by 13.9% in the 1st quarter. Iams Wealth Management LLC now owns 368 shares of the company’s stock worth $304,000 after acquiring an additional 45 shares in the last quarter. Finally, Clare Market Investments LLC increased its holdings in Eli Lilly and Company by 90.8% in the 1st quarter. Clare Market Investments LLC now owns 4,209 shares of the company’s stock worth $3,476,000 after acquiring an additional 2,003 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Leerink Partners reissued a “market perform” rating and issued a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 7th. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price for the company. in a report on Sunday, August 17th. Morgan Stanley reaffirmed an “overweight” rating and set a $1,135.00 price objective (up from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. HSBC raised shares of Eli Lilly and Company from a “reduce” rating to a “hold” rating and increased their price objective for the company from $675.00 to $700.00 in a report on Wednesday, August 27th. Finally, UBS Group cut their price objective on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $939.61.

Insider Buying and Selling

In related news, EVP Daniel Skovronsky purchased 1,000 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the transaction, the executive vice president directly owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Jamere Jackson purchased 200 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was bought at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the transaction, the director owned 9,402 shares of the company’s stock, valued at $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 4,514 shares of company stock valued at $2,894,841 over the last 90 days. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Down 0.6%

NYSE LLY opened at $820.69 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a market capitalization of $776.75 billion, a P/E ratio of 53.64, a P/E/G ratio of 1.15 and a beta of 0.47. Eli Lilly and Company has a one year low of $623.78 and a one year high of $937.00. The stock has a 50 day moving average price of $734.03 and a 200-day moving average price of $766.34.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s revenue was up 37.6% on a year-over-year basis. During the same period last year, the company earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.